Go Pro

Catherine Ramsey Schulte Analyst Performance

Analyst at Robert W. Baird

Catherine Ramsey Schulte is a stock analyst at Robert W. Baird in the healthcare sector, covering 8 publicly traded companies. Over the past year, Catherine Ramsey Schulte has issued 10 stock ratings, including and buy recommendations. While full access to Catherine Ramsey Schulte's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Catherine Ramsey Schulte's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
15 Last 6 Years
Buy Recommendations
83.33% 5 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy83.3%5 ratings
Hold16.7%1 ratings
Sell0.0%0 ratings

Out of 6 total stock ratings issued by Catherine Ramsey Schulte at Robert W. Baird, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
62.5% of companies on NASDAQ
5 companies
NYSE
37.5% of companies on NYSE
3 companies

Catherine Ramsey Schulte, an analyst at Robert W. Baird, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
8 companies
100.0%

Catherine Ramsey Schulte of Robert W. Baird specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
LIFE SCIENCES TOOLS & SERVICES
5 companies
62.5%
BIOTECHNOLOGY
3 companies
37.5%

Catherine Ramsey Schulte's Ratings History at Robert W. Baird

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Natera, Inc. stock logo
NTRA
Natera
8/7/2026Set Price Target$265.38$348.00
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
5/8/2026Set Price Target$16.33$22.00
Revvity Inc. stock logo
RVTY
Revvity
5/6/2026Set Price Target$92.32$117.00
Danaher Corporation stock logo
DHR
Danaher
4/17/2026Lower Price Target$193.38$249.00Outperform
GRAIL, Inc. stock logo
GRAL
GRAIL
2/20/2026Set Price Target$101.53$82.00
Illumina, Inc. stock logo
ILMN
Illumina
2/6/2026Set Price Target$120.96$137.00
Revvity Inc. stock logo
RVTY
Revvity
2/3/2026Set Price Target$102.72$129.00
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
11/20/2025Set Price Target$101.01$105.00
Revvity Inc. stock logo
RVTY
Revvity
10/24/2025Set Price Target$99.09$122.00
Qiagen N.V. stock logo
QGEN
Qiagen
10/2/2025Set Price Target$48.70$55.79Overweight
Danaher Corporation stock logo
DHR
Danaher
4/16/2025Set Price Target$190.85$231.00